Scott Patterson Positions Celera for its Next Race: Protein Analysis

Nov 05, 2001

Premium

AT A GLANCE

Name: Scott Patterson

Position: Vice President, Proteomics, Celera Genomics

Age: 39

Prior Experience: Developed Amgens proteomics program,investigator at Cold Spring Harbor Laboratory.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Johnson, Brexit, and Science

Nature News examines how science in the UK may fare as Boris Johnson, the next prime minister, pursues Brexit.

ICE Expands DNA Testing Sites

CNN reports that Immigration and Customs Enforcement in the US has expanded its DNA testing to seven sites along the southern border.

PNAS Papers Explore Neurogenesis Exosomes, More

In PNAS this week: role for exosomes in neuronal circuit development, tuberculosis pathogen enzymes, and more.

Undoing Obamacare protections could affect people's willingness to undergo genetic testing, Sarah Lawrence College's Laura Hercher and the University of Iowa College of Law's Anya Prince write at BuzzFeed News.

Featured White Papers

AlbuVoid Enrichment & Antibody Depletion – Tackling the Challenges of Serum Proteomics Part II

Stroma Liquid Biopsy, a pan-cancer biomarker panel of dysregulation derived from blood

Lipid Removal Sample Prep for Cell Response Applications

Aug

22

Featured Webinar

Biobanks and the Rise of Precision Medicine: Lessons from the Estonian Biobank

This webinar will discuss how the Estonian Biobank, a cohort of more than 165,000 participants, is addressing industry challenges with data management and collaboration in the transition to precision medicine.

Menu